Search results
Weyerhaeuser Q2 Earnings & Sales Top, Adjusted EBITDA Down Y/Y
Weyerhaeuser Company WY reported better-than-expected second-quarter 2026 financial results with adjusted earnings and net sales topping the Zacks Consensus Estimate. Year over year, the bottom line
EIX vs. CLPHY: Which Stock Is the Better Value Option?
Investors looking for stocks in the Utility - Electric Power sector might want to consider either Edison International (EIX) or CLP Holdings Ltd. (CLPHY). But which of these two stocks presents
IVZ vs. CG: Which Stock Is the Better Value Option?
Investors looking for stocks in the Financial - Investment Management sector might want to consider either Invesco (IVZ) or Carlyle Group (CG). But which of these two stocks presents investors with
NMR or JPM: Which Is the Better Value Stock Right Now?
Investors looking for stocks in the Financial - Investment Bank sector might want to consider either Nomura Holdings (NMR) or JPMorgan Chase & Co. (JPM). But which of these two stocks presents
UTHR or SDZNY: Which Is the Better Value Stock Right Now?
Investors interested in Medical - Drugs stocks are likely familiar with United Therapeutics (UTHR) and Sandoz Group AG Sponsored ADR (SDZNY). But which of these two companies is the best option for
XP or BX: Which Is the Better Value Stock Right Now?
Investors looking for stocks in the Financial - Miscellaneous Services sector might want to consider either XP Inc.A (XP) or Blackstone Inc. (BX). But which of these two stocks offers value
Zalando Q2 Earnings Call Highlights
Zalando (ETR:ZAL) said its second-quarter results kept the company on track for its 2026 profit targets, although it narrowed its full-year growth outlook to the lower half of its prior range after
New Strong Buy Stocks for August 4th
Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:
Ampol Limited CTXAY: This petroleum products company has seen the Zacks Consensus Estimate for its current year earnings
Is Schwab Fundamental U.S. Large Company ETF (FNDX) a Strong ETF Right Now?
The Schwab Fundamental U.S. Large Company ETF (FNDX) made its debut on 08/13/2013, and is a smart beta exchange traded fund that provides broad exposure to the Style Box - Large Cap Value category
ProPetro Q2 Loss Wider Than Expected, Revenues Beat Estimates
ProPetro Holding Corp. PUMP reported a second-quarter 2026 loss of 7 cents per share, wider than the Zacks Consensus Estimate of a loss of 1 cent. This was due to higher fleet activation costs
KROS Q2 Earnings Miss as Revenues Fall to Zero, Pipeline in Focus
Keros Therapeutics KROS reported second-quarter 2026 loss of $1.45 per share, wider than the Zacks Consensus Estimate of a loss of $1.25. The reported loss widened 91% from 76 cents per share
Cadiz (CDZI) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
Cadiz (CDZI) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2026. This widely-known consensus outlook gives a
PRGS vs. MSFT: Which Stock Is the Better Value Option?
Investors looking for stocks in the Computer - Software sector might want to consider either Progress Software (PRGS) or Microsoft (MSFT). But which of these two stocks offers value investors a
COO vs. MMSI: Which Stock Should Value Investors Buy Now?
Investors interested in Medical - Dental Supplies stocks are likely familiar with The Cooper Companies (COO) and Merit Medical (MMSI). But which of these two companies is the best option for those
DECK or IDEXY: Which Is the Better Value Stock Right Now?
Investors interested in Retail - Apparel and Shoes stocks are likely familiar with Deckers (DECK) and Industria de Diseno Textil SA (IDEXY). But which of these two companies is the best option for
Jacobs Q3 Earnings Meet Estimates, Revenues Up Y/Y, Stock Down
Jacobs Solutions Inc.’s J third-quarter fiscal 2026 (ended June 26, 2026) adjusted earnings met the Zacks Consensus Estimate but grew year over year. However, revenues topped the consensus mark and
Kymera Therapeutics Q2 Earnings Call Highlights
Key Points
- Interested in Kymera Therapeutics, Inc.? Here are five stocks we like better.
- KT-621 atopic dermatitis trial enrollment is complete about six months ahead of schedule, with top-line
Can Segment Strength Offset Headwinds for BD Stock Before Q3 Earnings?
Becton Dickinson and Company BDX, popularly known as BD, is scheduled to report third-quarter fiscal 2026 results on Aug. 6, before market open.
In the last reported quarter, the company’s adjusted




